Literature DB >> 22017263

Choroideremia: a review of general findings and pathogenesis.

Razek Georges Coussa1, Elias I Traboulsi.   

Abstract

Choroideremia (CHM) is an X-linked retinal dystrophy belonging to the family of blinding disorders. It is characterized by progressive degeneration of the choriocapillaris, retinal pigment epithelium and photoreceptors. CHM is caused by mutations in the Rab Escort Protein 1 (REP-1) gene, which encodes a protein involved in vesicular trafficking. This paper gives an overview of the clinical features, visual function, biochemistry, histology, molecular genetics, pathogenesis, diagnosis and treatment of CHM.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22017263     DOI: 10.3109/13816810.2011.620056

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  48 in total

1.  Visual Function at the Atrophic Border in Choroideremia Assessed with Adaptive Optics Microperimetry.

Authors:  William S Tuten; Grace K Vergilio; Gloria J Young; Jean Bennett; Albert M Maguire; Tomas S Aleman; David H Brainard; Jessica I W Morgan
Journal:  Ophthalmol Retina       Date:  2019-05-08

2.  Retinal dystrophy and subretinal drusenoid deposits in female choroideremia carriers.

Authors:  Vittoria Murro; Dario Pasquale Mucciolo; Ilaria Passerini; Simona Palchetti; Andrea Sodi; Gianni Virgili; Stanislao Rizzo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-27       Impact factor: 3.117

3.  High-resolution adaptive optics retinal imaging of cellular structure in choroideremia.

Authors:  Jessica I W Morgan; Grace Han; Eva Klinman; William M Maguire; Daniel C Chung; Albert M Maguire; Jean Bennett
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-04       Impact factor: 4.799

4.  Cellular resolution maps of X chromosome inactivation: implications for neural development, function, and disease.

Authors:  Hao Wu; Junjie Luo; Huimin Yu; Amir Rattner; Alisa Mo; Yanshu Wang; Philip M Smallwood; Bracha Erlanger; Sarah J Wheelan; Jeremy Nathans
Journal:  Neuron       Date:  2014-01-08       Impact factor: 17.173

5.  Two-year progression analysis of RPE65 autosomal dominant retinitis pigmentosa.

Authors:  Ruben Jauregui; Karen Sophia Park; Stephen H Tsang
Journal:  Ophthalmic Genet       Date:  2018-08       Impact factor: 1.803

6.  Multimodal assessment of choroideremia patients defines pre-treatment characteristics.

Authors:  Immanuel P Seitz; Ahmad Zhour; Susanne Kohl; Pablo Llavona; Tobias Peter; Barbara Wilhelm; Eberhart Zrenner; Marius Ueffing; Karl Ulrich Bartz-Schmidt; M Dominik Fischer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-03-07       Impact factor: 3.117

7.  Natural History of the Central Structural Abnormalities in Choroideremia: A Prospective Cross-Sectional Study.

Authors:  Tomas S Aleman; Grace Han; Leona W Serrano; Nicole M Fuerst; Emily S Charlson; Denise J Pearson; Daniel C Chung; Anastasia Traband; Wei Pan; Gui-Shuang Ying; Jean Bennett; Albert M Maguire; Jessica I W Morgan
Journal:  Ophthalmology       Date:  2016-12-13       Impact factor: 12.079

8.  CHOROIDEREMIA: Retinal Degeneration With an Unmet Need.

Authors:  Mark E Pennesi; David G Birch; Jacque L Duncan; Jean Bennett; Aniz Girach
Journal:  Retina       Date:  2019-11       Impact factor: 4.256

9.  Quantitative optical coherence tomography angiography of vascular abnormalities in the living human eye.

Authors:  Yali Jia; Steven T Bailey; Thomas S Hwang; Scott M McClintic; Simon S Gao; Mark E Pennesi; Christina J Flaxel; Andreas K Lauer; David J Wilson; Joachim Hornegger; James G Fujimoto; David Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-20       Impact factor: 11.205

10.  High-resolution images of retinal structure in patients with choroideremia.

Authors:  Reema Syed; Sanna M Sundquist; Kavitha Ratnam; Shiri Zayit-Soudry; Yuhua Zhang; J Brooks Crawford; Ian M MacDonald; Pooja Godara; Jungtae Rha; Joseph Carroll; Austin Roorda; Kimberly E Stepien; Jacque L Duncan
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.